A Comprehensive Clinical Review: Mechanisms, Diagnosis, Pathology, Glomerular Disease, and Management
Author: Andrew Bland, MD, MBA, MS
CTLA-4 (cytotoxic T-lymphocyte–associated protein 4) functions as an early-phase inhibitory checkpoint that is upregulated on the T cell surface within hours of T cell receptor activation. It competes with CD28 for binding to B7-1 (CD80) and B7-2 (CD86) on the antigen-presenting cell surface. Because CTLA-4 binds B7 ligands with approximately 20-fold higher affinity than CD28, its expression effectively outcompetes the costimulatory signal, dampening T cell activation, proliferation, and cytokine production. Ipilimumab, a fully human IgG1 monoclonal antibody, blocks CTLA-4, removing this early inhibitory brake. The net result is broader T cell activation, greater clonal expansion, and a higher probability of autoreactive T cell engagement — which underlies the higher overall irAE rate seen with anti-CTLA-4 therapy compared to anti-PD-1 monotherapy (1,6).
PD-1 (programmed death-1) operates as a later-phase inhibitory receptor expressed on activated T cells, B cells, and NK cells. Its ligands, PD-L1 and PD-L2, are expressed on tumor cells, antigen-presenting cells, and peripheral tissues including the kidney. When PD-1 engages PD-L1, SHP-2 phosphatase is recruited to the T cell receptor complex, dephosphorylating key signaling intermediates and attenuating T cell effector function, cytokine production, and survival signaling. This is the peripheral tolerance mechanism that protects normal tissues from ongoing immune attack (1,6).
Anti-PD-1 agents (nivolumab, pembrolizumab, cemiplimab) and anti-PD-L1 agents (atezolizumab, avelumab, durvalumab) block this interaction, reactivating T cells in the tumor microenvironment but also in peripheral tissues where PD-L1 is expressed — including renal tubular epithelium. Renal tubular cells constitutively express PD-L1, which protects them from immune-mediated injury under normal conditions. When PD-1/PD-L1 blockade removes this protection, tubular cells become vulnerable to T cell–mediated attack (1,3).
Combination therapy (anti-CTLA-4 plus anti-PD-1 or anti-PD-L1) produces the highest rates of immune-related adverse events across all organ systems, including the kidney. By simultaneously removing early-phase (CTLA-4) and late-phase (PD-1) immune checkpoints, combination therapy generates broader and more intense T cell activation, greater clonal diversity of autoreactive T cells, and a higher frequency and severity of off-target immune toxicity. The odds ratio for ICI-AKI with combination therapy versus monotherapy is approximately 3.2 (2).
The kidney is normally protected from T cell–mediated injury by two principal mechanisms: PD-L1 expression on renal tubular epithelium engages PD-1 on infiltrating T cells to induce T cell exhaustion, and regulatory T cells (Tregs) suppress autoreactive T cell clones directed against renal antigens. ICI therapy disrupts both mechanisms: PD-1/PD-L1 blockade removes the tubular self-defense mechanism, and anti-CTLA-4 therapy reduces Treg number and function. The result is loss of peripheral tolerance to renal tubular antigens, enabling autoreactive CD8+ cytotoxic T cells to infiltrate the interstitium and attack tubular epithelium (1,3).
Pathway 1 — Direct Autoimmune ATIN: ICIs reactivate pre-existing autoreactive T cell clones that recognize renal tubular cell surface antigens (possibly shared with tumor-associated antigens). These T cells were previously held in check by CTLA-4 and PD-1 pathways. Upon checkpoint blockade, they mount a nephritogenic immune response against tubular epithelium.
Pathway 2 — Drug-Amplified ATIN: Concurrent medications such as proton pump inhibitors or NSAIDs serve as haptens that prime a drug-specific T cell response. Under normal checkpoint regulation, this response remains subclinical. ICI therapy amplifies it beyond the threshold of clinical disease, producing AIN that is attributable to the combination of the drug hapten and the checkpoint blockade rather than to either alone (1,2).
ICI-ATIN develops at a median of 14 weeks after ICI initiation, with a broad range extending from two days to 18 or more months (IQR 6–47 weeks) (2). The peak incidence occurs during weeks 8 through 20 in most series.
| Risk Factor | Odds Ratio | Clinical Significance |
|---|---|---|
| Combination ICI therapy (anti-CTLA-4 + anti-PD-1) | 3.2 | Strongest risk factor; incidence ~10% |
| Concurrent PPI use | 2.1 | Modifiable; discontinue PPIs when possible |
| Pre-existing CKD | — | Reduced nephron mass amplifies functional impact |
| Age >60 years | — | Increased immune dysregulation substrate |
| Prior irAE in other organ | — | Suggests systemic predisposition |
| Melanoma / RCC tumor type | — | Higher rates than NSCLC |
The clinical presentation of ICI-ATIN is most commonly asymptomatic or minimally symptomatic, discovered incidentally on routine laboratory monitoring. The patient typically presents without urinary complaints and with only vague constitutional symptoms such as mild fatigue or reduced appetite. Urine output is typically preserved; oliguria is unusual and should prompt consideration of alternative diagnoses (1,2).
Sterile pyuria (>5 WBC/hpf in the absence of bacteriuria) is present in 60–80% of affected patients. WBC casts are the most specific urinary finding for ATIN — their presence confirms that the pyuria is of renal and specifically tubulointerstitial origin. Eosinophiluria (>1% on Hansel stain) is less reliably present in ICI-ATIN than in classic drug-induced AIN, reflecting the predominantly T-cell–driven rather than eosinophil-mediated immune response (1,3).
Proteinuria is characteristically subnephrotic (<2 g/g creatinine). The Cortazar single-center series reported a median UPCR of 0.48 g/g (4). Proteinuria >2 g/day, and particularly >3.5 g/day (nephrotic range), should raise concern for concurrent glomerular disease.
Typically absent or minimal. Prominent hematuria (>10–15 RBCs/hpf), dysmorphic red cells, or RBC casts suggest glomerular pathology and should prompt urgent evaluation for crescentic GN, ANCA vasculitis, or anti-GBM disease (1,4).
FENa is typically >2%, reflecting inappropriate sodium wasting from inflamed tubules. Urine osmolality <300 mOsm/kg is consistent with tubular concentrating defect. Elevated urine beta-2 microglobulin provides additional evidence of proximal tubular dysfunction (1).
Three convergent criteria, when simultaneously present, establish a high-probability diagnosis of ICI-ATIN (>90% likelihood) without biopsy:
| Criterion | Definition |
|---|---|
| Temporal | Acute creatinine elevation 6–20 weeks after ICI initiation, no alternative explanation within 24–48 hours |
| Urinary | Sterile pyuria ± WBC casts, subnephrotic proteinuria <2 g/day |
| Functional | FENa >2% or urine osmolality <300–400 mOsm/kg (tubular dysfunction) |
The most common cause of AKI in hospitalized patients. Volume depletion produces concentrated urine (Uosm >600) with low FENa (<1%). Should resolve with volume replacement within 24–48 hours; failure to improve strengthens the case for intrinsic renal pathology.
From concurrent platinum-based chemotherapy, aminoglycosides, or iodinated contrast. Produces granular or pigmented waxy casts — not WBC casts — and presents within days of nephrotoxic exposure rather than weeks to months after ICI.
From tumor progression, retroperitoneal lymphadenopathy, or ureteral involvement. Exclude with renal ultrasound in any patient with AKI and pelvic or retroperitoneal malignancy.
May produce pyuria and WBC casts indistinguishable from ATIN; a positive urine culture (>100,000 CFU/mL) establishes this diagnosis. Sterile pyuria — pyuria without bacteriuria — strongly favors ATIN over infection.
Suggested by heavy proteinuria (>2 g/day), prominent hematuria with dysmorphic red cells or RBC casts, or hypoalbuminemia. The Cortazar 2020 study identified concurrent glomerular pathology in 27% of biopsied patients (2).
The Cortazar/MD Anderson approach advocates for early biopsy in all stage 2 or higher AKI, performed before high-dose steroid initiation. The Brigham approach recommends proceeding empirically with corticosteroids in classic ATIN presentations, reserving biopsy for atypical features, severe AKI, lack of steroid response, or prominent glomerular features (1,2,6).
The dominant finding is a dense inflammatory infiltrate within the renal interstitium, composed predominantly of mononuclear cells — lymphocytes predominate, with plasma cells, macrophages, and monocytes in variable numbers. Tubulitis (lymphocyte infiltration through the tubular basement membrane into the tubular epithelium) reflects active cytotoxic T cell attack. Eosinophils tend to be sparse compared to classic drug-induced AIN. Glomeruli appear normal or near-normal — an important negative finding (1,3).
| Severity | Interstitial Involvement | Prognosis |
|---|---|---|
| Mild | <10%, preserved tubular architecture | Excellent recovery |
| Moderate | 10–50% with focal tubular necrosis | Good recovery expected |
| Severe | >50% with extensive tubular necrosis and early fibrosis | Reduced likelihood of complete recovery |
Characteristically sparse or negative. No linear or granular immune complex deposits along tubular or glomerular basement membranes. This paucity of immune complex deposition is consistent with T-cell–mediated rather than antibody-mediated pathogenesis. In concurrent glomerular disease, IF will be positive and reflect the specific pattern (1,3,5).
In pure ICI-ATIN, no electron-dense immune complex deposits are identified. When concurrent glomerular disease is present, EM becomes essential: foot process effacement confirms podocytopathy (MCD/FSGS); subepithelial deposits confirm membranous; subendothelial deposits indicate immune-complex GN; endothelial swelling with platelet-fibrin thrombi characterizes TMA.
The Cortazar 2020 multicenter study (138 ICI-AKI patients, 93 biopsied) established the pathologic distribution (2):
| Pathologic Pattern | Frequency | First-Line | Escalation |
|---|---|---|---|
| Pure ATIN | 71% | Prednisone 0.5–1 mg/kg/day | Add MMF if refractory |
| ATIN + glomerular | 19% | Prednisone 1 mg/kg/day | Rituximab or MMF |
| Pure glomerular | 4% | Prednisone 1–2 mg/kg/day | Rituximab or cyclophosphamide |
| TMA | <2% | High-dose steroids | Plasma exchange (center-dependent) |
The Kitchlu 2021 systematic review of 112 ICI-associated glomerular disease patients identified: pauci-immune crescentic GN (28.3%), podocytopathies including MCD and FSGS (26.4%), immune-complex GN including lupus-like and membranous (18.9%), MPGN including C3-GN (9.8%), ANCA-positive vasculitis (8.0%), and other patterns including IgA nephropathy (8.6%) (5).
Presents with sudden-onset nephrotic syndrome (>3.5 g/day proteinuria, edema, hypoalbuminemia), typically 2–8 weeks after ICI initiation, often with preserved serum creatinine. EM is diagnostic: widespread podocyte foot process effacement. IF is negative or shows only trace IgM. Mechanism involves ICI-restored T cells producing lymphokines (IL-4, IL-13) that disrupt podocyte cytoskeletal architecture through STAT6 activation. Management: ICI hold, prednisone 0.5–1 mg/kg/day, with 80–90% achieving complete remission within 4–12 weeks. Steroid-sparing options: MMF, tacrolimus, or rituximab for relapsing cases (5).
Presents with proteinuria plus hematuria with dysmorphic RBCs and RBC casts, variable AKI, and — critically — negative or only low-titer ANA with absent anti-dsDNA and normal complement. Biopsy: Class III or IV pattern with full-house IF (IgG, IgA, IgM, C3, C1q) and subendothelial electron-dense deposits. Permanent ICI discontinuation recommended. Class IV disease requires prednisone 1–2 mg/kg/day plus MMF or cyclophosphamide induction. Renal remission in 50–70%; ESRD in 10–20% (5).
The most common GN pattern in ICI-associated kidney injury. Presents as rapidly progressive AKI with heavy proteinuria and prominent dysmorphic hematuria with RBC casts. ANCA-negative, ANA-negative, anti-GBM-negative. Biopsy: necrotizing segmental capillary loop injury with crescent formation, pauci-immune IF. This is a nephrology emergency. Treatment parallels primary ANCA vasculitis: prednisone 1–2 mg/kg/day plus rituximab (375 mg/m² IV weekly x4, preferred) or cyclophosphamide. Plasma exchange when Cr >5 mg/dL. Renal recovery in 40–50%; ESRD in 15–25% (5,8).
Presents with nephrotic syndrome (often >8–10 g/day proteinuria), preserved creatinine, and negative PLA2R antibody — the key distinguishing feature from primary membranous. Biopsy: thickened GBM with subepithelial deposits, granular IgG + C3 on IF. Rituximab is preferred treatment. Maximal-dose ACE-I/ARB essential. Anticoagulation when albumin <2.5 g/dL. ICI rechallenge generally not recommended (5).
C3-dominant IF (C3 ≥2+ with immunoglobulin absent or <1+), suggesting alternative complement pathway dysregulation. Presentation: hematuria, non-nephrotic proteinuria, variable AKI, normal C3/C4. Management: ACE-I/ARB for mild disease; prednisone for progressive disease; eculizumab for steroid-refractory cases (5).
| Pattern | Key Presentation | Biopsy Hallmark | Serology | First-Line Tx | Prognosis |
|---|---|---|---|---|---|
| MCD/Podocytopathy | Nephrotic, normal Cr | Foot process effacement (EM) | Negative | Prednisone 0.5–1 mg/kg | Excellent (80–90% CR) |
| Lupus-like | Hematuria + nephrotic | Class III/IV, full-house IF | ANA−, C3/C4 nl | Prednisone + MMF/cyclo | Good (50–70% remission) |
| Pauci-immune crescent | RPGN, RBC casts | Crescents, pauci-immune IF | ANCA−, ANA− | Prednisone + rituximab | Guarded (40–50% CR) |
| Membranous | Nephrotic, normal Cr | Subepithelial deposits (EM) | PLA2R− | Rituximab + ACE-I | Moderate (50–70% PR) |
| C3-GN | Hematuria, mild AKI | C3-dominant IF | C3/C4 nl | Prednisone ± eculizumab | Moderate (50–60%) |
| IgA Nephropathy | Hematuria, mild AKI | IgA-dominant IF | Normal | Prednisone ± MMF | Moderate (varies) |
PPIs are well-established causes of AIN that produce a histologic pattern indistinguishable from ICI-related ATIN: both conditions show dense lymphocytic interstitial infiltration, tubular injury, sterile pyuria, and subnephrotic proteinuria (1,7).
The essential epidemiologic and outcomes foundation for current understanding of ICI-AKI (2). This study enrolled 138 patients with ICI-AKI across 12 U.S. academic medical centers, with 276 ICI-treated controls.
| Parameter | Finding |
|---|---|
| Median time ICI → AKI | 14 weeks (IQR 6–47) |
| Combination ICI therapy OR | 3.2 (p<0.001) |
| PPI use OR | 2.1 (p=0.02) |
| Pure ATIN on biopsy | 71% |
| ATIN + glomerular disease | 19% |
| Steroid response (complete + partial) | 87% (44% complete, 43% partial) |
| Median time to Cr plateau after steroids | 14 days |
| Median time to Cr ≤1.2x baseline | 28 days |
| Rechallenge success rate | 77% (23/30) without recurrent AKI |
| CTCAE Grade | Creatinine Change | KDIGO Stage | ICI Management |
|---|---|---|---|
| Grade 1 | 1.5–1.9x baseline | Stage 1 | Continue ICI with monitoring |
| Grade 2 | 2.0–2.9x baseline | Stage 2 | Hold ICI, initiate steroids |
| Grade 3 | ≥3x baseline or >3 mg/dL | Stage 3 | Hold ICI, high-dose steroids |
| Grade 4 | Dialysis-dependent | Stage 3 (dialysis) | Permanent ICI discontinuation |
Weekly labs for 4 weeks, then every 2 weeks if stable. Discontinue all PPIs and NSAIDs. Hold diuretics unless essential. 60–70% remain stable; 20–30% progress to Grade 2.
Immediate ICI hold and prednisone 0.5–1 mg/kg/day PO. IV methylprednisolone 1 g daily x3 days for severe or rapidly progressive presentations. Steroid taper: full dose for 10–14 days, then reduce ~20 mg every 5–7 days. Minimum total taper: 4–6 weeks. Rapid tapers increase relapse rates from ~10% to 30–40%.
Renal emergency. IV methylprednisolone 1 g daily x3 days, then prednisone 1–2 mg/kg/day. Mandatory nephrology consultation. Kidney biopsy strongly recommended. Dialysis initiation for K >6.0 mEq/L refractory to medical management, pH <7.2, volume overload with hypoxia, or uremic symptoms. ~50–60% of Grade 3–4 patients who require dialysis recover renal function within 4–6 weeks.
Permanent ICI discontinuation. IV methylprednisolone 1 g daily x5 days plus steroid-sparing agent. Kidney biopsy mandatory. ~50% recover off dialysis; ~30% progress to ESRD; ~20% expire from cancer or other complications (3).
Defined as absence of creatinine improvement or worsening despite 3–5 days of high-dose corticosteroids.
| Agent | Dose | Mechanism | Response Rate | Key Considerations |
|---|---|---|---|---|
| MMF | 500 mg q6h PO (2–3 g/day) | IMPDH inhibition | ~70% | GI intolerance (20–30%), neutropenia |
| Rituximab | 375 mg/m² IV weekly x4 | CD20+ B-cell depletion | ~80% | HBV screening mandatory; cost |
| Infliximab | 5 mg/kg IV wks 0, 2, 6 | TNF-α blockade | ~60–70% | Do NOT use with PD-L1 inhibitors; TB screening |
| Cyclophosphamide | 500–750 mg/m² IV monthly | Alkylating agent | ~85% | Reserved for crescentic GN; hemorrhagic cystitis risk |
Rechallenge is appropriate when: Grade 1–2 initial AKI, complete or near-complete recovery (Cr ≤1.2x baseline), pure ATIN on biopsy (if performed), minimum 2-month interval, no steroid-refractory history, and meaningful cancer control benefit expected (2).
| Strategy | Approach | Success Rate |
|---|---|---|
| Same ICI at full dose | Most common; weekly labs x4 wks, then q2wk x8 wks | 77% |
| Switch to alternative ICI | e.g., nivolumab → pembrolizumab, or PD-1 → PD-L1 | ~50–60% |
| Extended dosing interval | e.g., nivolumab Q2W → Q4W | Limited data |
ICIs restore immune recognition of allograft antigens, producing a 10–20-fold increase in rejection risk. When AKI develops, the differential must include acute rejection (T-cell mediated, antibody-mediated, or both), ICI-ATIN in the allograft, and the combination. Biopsy is mandatory. Rechallenge is generally not recommended unless the malignancy is extremely aggressive and the graft is considered expendable (9).
Most ICI agents are cleared via the mononuclear phagocyte system rather than renal excretion. ICI-AKI does not manifest as creatinine rise in anuric patients. Standard steroid protocols apply (3).
Reduced nephron mass leaves less buffering capacity against interstitial inflammation. KDIGO staging is more informative than CTCAE grading in this population. Biweekly laboratory monitoring at minimum. ICI rechallenge after AKI in patients with eGFR <30 is generally not recommended (3).
Approximately 30–40% of patients develop progressive CKD over 6–12 months following ICI-AKI. 10–15% progress to ESRD within 2 years. Predictors of CKD progression: older age, baseline CKD, multi-agent immunosuppression, crescentic GN at biopsy, and incomplete Cr recovery at 3 months (2,3).
ICI-associated kidney injury is, in its dominant form, acute tubulointerstitial nephritis — a T-cell–mediated, steroid-responsive immune-related adverse event pathologically distinct from prerenal azotemia, classic ATN, and obstructive nephropathy. Its recognition requires systematic laboratory surveillance, attention to the urinary signature of sterile pyuria and WBC casts, and awareness of the 8–20 week timeline.
Biopsy confirms ATIN in the majority and identifies the 27% with concurrent glomerular disease requiring escalated immunosuppression. The management approach recognizes that ICI-AKI is not a permanent contraindication to cancer therapy: grade-based steroid protocols achieve recovery in the vast majority, and carefully selected rechallenge succeeds in approximately 77% of cases.
The nephrologist’s role — identifying the diagnosis early, interpreting the biopsy, titrating immunosuppression, and advising on rechallenge eligibility — is central to an oncologic care model that simultaneously preserves renal function and maintains access to life-prolonging cancer therapy.
Andrew Bland, MD, MBA, MS | Clinical Mastery Series | Urine Nephrology Now
© 2026. For educational use only.